ArticleBMC cancer2025

A phase II trial of hepatic ablation of metastases to modulate and enhance immunotherapy response in non-small cell lung cancer (HAMMER-NSCLC).

Matthew T McMillan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.